204 related articles for article (PubMed ID: 29081307)
1. Efficacy of vortioxetine in working patients with generalized anxiety disorder.
Christensen MC; Loft H; Florea I; McIntyre RS
CNS Spectr; 2019 Apr; 24(2):249-257. PubMed ID: 29081307
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorder.
Mahableshwarkar AR; Jacobsen PL; Serenko M; Chen Y
Hum Psychopharmacol; 2014 Jan; 29(1):64-72. PubMed ID: 24424707
[TBL] [Abstract][Full Text] [Related]
3. Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial.
Bidzan L; Mahableshwarkar AR; Jacobsen P; Yan M; Sheehan DV
Eur Neuropsychopharmacol; 2012 Dec; 22(12):847-57. PubMed ID: 22898365
[TBL] [Abstract][Full Text] [Related]
4. Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: a systematic review and meta-analysis.
Pae CU; Wang SM; Han C; Lee SJ; Patkar AA; Masand PS; Serretti A
J Psychiatr Res; 2015 May; 64():88-98. PubMed ID: 25851751
[TBL] [Abstract][Full Text] [Related]
5. Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States.
Rothschild AJ; Mahableshwarkar AR; Jacobsen P; Yan M; Sheehan DV
Eur Neuropsychopharmacol; 2012 Dec; 22(12):858-66. PubMed ID: 22901736
[TBL] [Abstract][Full Text] [Related]
6. Vortioxetine in patients with major depressive disorder and high levels of anxiety symptoms: An updated analysis of efficacy and tolerability.
Adair M; Christensen MC; Florea I; Loft H; Fagiolini A
J Affect Disord; 2023 May; 328():345-354. PubMed ID: 36708956
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of vortioxetine in patients with major depressive disorder comorbid with generalized anxiety disorder: Results of the RECONNECT study.
Christensen MC; Schmidt S; Grande I
J Psychopharmacol; 2022 May; 36(5):566-577. PubMed ID: 35499104
[TBL] [Abstract][Full Text] [Related]
8. A randomised, double-blind, placebo-controlled, duloxetine-referenced study of the efficacy and tolerability of vortioxetine in the acute treatment of adults with generalised anxiety disorder.
Mahableshwarkar AR; Jacobsen PL; Chen Y; Simon JS
Int J Clin Pract; 2014 Jan; 68(1):49-59. PubMed ID: 24341301
[TBL] [Abstract][Full Text] [Related]
9. Vortioxetine treatment for generalised anxiety disorder: a meta-analysis of anxiety, quality of life and safety outcomes.
Qin B; Huang G; Yang Q; Zhao M; Chen H; Gao W; Yang M
BMJ Open; 2019 Nov; 9(11):e033161. PubMed ID: 31784448
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of vortioxetine in patients with major depressive disorder reporting childhood or recent trauma.
Christensen MC; Florea I; Loft H; McIntyre RS
J Affect Disord; 2020 Feb; 263():258-266. PubMed ID: 31818787
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of vortioxetine in patients with major depressive disorder and co-morbid generalized anxiety disorder in routine clinical practice: A subgroup analysis of the RELIEVE study.
Almeida SS; Christensen MC; Simonsen K; Adair M
J Psychopharmacol; 2023 Mar; 37(3):279-288. PubMed ID: 36377523
[TBL] [Abstract][Full Text] [Related]
12. Vortioxetine Treatment for Anxiety Disorder: A Meta-Analysis Study.
Yee A; Ng CG; Seng LH
Curr Drug Targets; 2018; 19(12):1412-1423. PubMed ID: 29149828
[TBL] [Abstract][Full Text] [Related]
13. Duloxetine versus placebo in the treatment of patients with generalized anxiety disorder in China.
Wu WY; Wang G; Ball SG; Desaiah D; Ang QQ
Chin Med J (Engl); 2011 Oct; 124(20):3260-8. PubMed ID: 22088518
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study.
Jacobsen PL; Harper L; Chrones L; Chan S; Mahableshwarkar AR
Int Clin Psychopharmacol; 2015 Sep; 30(5):255-64. PubMed ID: 26020712
[TBL] [Abstract][Full Text] [Related]
15. Putative Antidepressant Effect of Chamomile (
Amsterdam JD; Li QS; Xie SX; Mao JJ
J Altern Complement Med; 2020 Sep; 26(9):813-819. PubMed ID: 31808709
[No Abstract] [Full Text] [Related]
16. Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder.
Baldwin DS; Loft H; Florea I
Int Clin Psychopharmacol; 2012 Jul; 27(4):197-207. PubMed ID: 22475889
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.
Gelenberg AJ; Lydiard RB; Rudolph RL; Aguiar L; Haskins JT; Salinas E
JAMA; 2000 Jun; 283(23):3082-8. PubMed ID: 10865302
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Vilazodone in Patients With Generalized Anxiety Disorder: A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Trial.
Durgam S; Gommoll C; Forero G; Nunez R; Tang X; Mathews M; Sheehan DV
J Clin Psychiatry; 2016 Dec; 77(12):1687-1694. PubMed ID: 27232052
[TBL] [Abstract][Full Text] [Related]
19. Effects of extended-release quetiapine fumarate on long-term functioning and sleep quality in patients with Generalized Anxiety Disorder (GAD): data from a randomized-withdrawal, placebo-controlled maintenance study.
Sheehan DV; Svedsäter H; Locklear JC; Eriksson H
J Affect Disord; 2013 Dec; 151(3):906-13. PubMed ID: 24135509
[TBL] [Abstract][Full Text] [Related]
20. Vortioxetine for attention deficit hyperactivity disorder in adults: A randomized, double-blind, placebo-controlled, proof-of-concept study.
Biederman J; Lindsten A; Sluth LB; Petersen ML; Ettrup A; Eriksen HF; Fava M
J Psychopharmacol; 2019 Apr; 33(4):511-521. PubMed ID: 30843450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
